Uracyst

Type: Product
Name: Uracyst
First reported Oct 09 2014 - Updated Oct 09 2014 - 1 reports

Navamedic ASA : Market Review September 2014

Medical Nutrition (the Nordics) Navamedic attended SSIEM, the biggest and most important congress for professionals and companies working within the area of inborn errors of metabolism (IEM).SwedenNYDA® launch and campaign in Sweden In September NYDA® ... [Published 4 Traders - Oct 09 2014]
First reported Oct 09 2014 - Updated Oct 09 2014 - 1 reports

Tribute Pharma: Drop Your Tensions With This Deal

Summary With an existing diverse portfolio of products and the recent acquisition of Novartis' products, Tribute, a specialty pharma company, is chugging along towards positive EBITDA in 2015. The higher margin primary care products (CAMBIA, Bezalip ... [Published Seeking Alpha - Oct 09 2014]
First reported Sep 30 2014 - Updated Sep 30 2014 - 1 reports

3 Potentially Game-Changing Biotech

Good management. Promising therapies in the pipeline. Marketed products that bolster the bottom line. Investors crave these bread-and-butter qualities in small-cap biotech and medtech companies. Anita Dushyanth of Zacks Investment Research relies on the ... [Published Equities.com - Sep 30 2014]
First reported Sep 25 2014 - Updated Sep 25 2014 - 3 reports

Tribute Pharmaceuticals receives another Uracyst patent

Mr. Scott Langille reportsTRIBUTE PHARMACEUTICALS RECEIVES 4TH URACYST(R) PATENT IN UNITEDSTATESTribute Pharmaceuticals Canada Inc. has received an additional patent from the U.S. Patent and Trademark Office (USPTO) for intellectual property that is central ... [Published Stockwatch - Sep 25 2014]

Quotes

..." Mr. Harris further stated, "The company has currently accelerated plans to maximize the value of this unique product in the U S market especially when considering other recent [merger and acquisition] transactions in this market."

More Content

All (6) | News (5) | Reports (0) | Blogs (1) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Navamedic ASA : Market Review September 2014 [Published 4 Traders - Oct 09 2014]
Tribute Pharma: Drop Your Tensions With This Deal [Published Seeking Alpha - Oct 09 2014]
3 Potentially Game-Changing Biotech [Published Equities.com - Sep 30 2014]
Tribute Pharmaceuticals receives another Uracys... [Published Stockwatch - Sep 25 2014]
Tribute Pharmaceuticals Receives 4th Uracyst(R)... [Published InvestorPoint.com - Sep 25 2014]
Tribute Pharmaceuticals Receives 4th Uracyst(R)... [Published Marketwire - Breaking News Releases - Sep 25 2014]
1
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Tribute Pharmaceuticals Receives 4th Uracyst(R)... [Published Marketwire - Breaking News Releases - Sep 25 2014]
<p style="text-align:left;"&gt;MILTON, ONTARIO--(Marketwired - Sept. 25, 2014) - Tribute Pharmaceuticals Canada Inc. (OTCQX:TBUFF)(TSX VENTURE:TRX) ("Tribute" or the "Company"), today announced that it has received an additional patent from the U.S. Patent ...
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.